Vertex Pharmaceuticals has received approval from the Therapeutic Goods Administration for ALYFTREK, a once-daily, next-generation CFTR modulator for Australians living with cystic fibrosis.
Vertex secures TGA approval for next-generation cystic fibrosis therapy
November 19, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News
